Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.
Durvalumab, an FDA-approved immunotherapy, met its second primary endpoint of overall survival in the phase 3 PACIFIC trial for stage 3 non-small cell lung cancer.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.
Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, and Specialty Pharmacy Times, the most read publication among specialty pharmacists, have been honored with the 2018 Hermes Creative Awards.
Ibrutinib plus obintuzumab improved progression-free survival in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.